The clinical value of measuring concentrations of methylmalonic acid in serum (S-MMA) as an aid in the diagnosis of cobalamin deficiency has recently aroused interest. In 58 healthy subjects, ages 40-68 years, we found a 0.95 reference interval of 0.05-0.37 prnol/L (mean 0.21, SD 0.094). In 33 of the subjects, who were studied further, day-to-day variation (SD) was 0.031 pmol/L. Intake of food had no effect. Weekly and three-monthly intra-individual variations were both 0.038 .anol/L. In all seven subjects with S-MMA >0.30 /Lmol/L, the concentrations declined significantly after intramuscular administration of cobalamin. No significant difference was found between mean serum cobalamin concentrations in these seven and in the remaining subjects. We have also established the normal response of S-MMA to standardized oral loading of L-isoleucine: 100 mmol caused a significant average S-MMA increase of 0.072 zmol/L before cobalamin administration vs 0.013 .mol/L after cobalamin, without significant relation to initial S-MMA values. Our results provide a necessary background for interpretation of S-MMA measurements in clinical studies.
The clinical value of measuring concentrations of methylmalonic acid in serum (S-MMA) as an aid in the diagnosis of cobalamin deficiency has recently aroused interest. In 58 healthy subjects, ages 40-68 years, we found a 0.95 reference interval of 0.05-0.37 prnol/L (mean 0.21, SD 0.094). In 33 of the subjects, who were studied further, day-to-day variation (SD) was 0.031 pmol/L. Intake of food had no effect. Weekly and three-monthly intra-individual variations were both 0.038 .anol/L. In all seven subjects with S-MMA >0.30 /Lmol/L, the concentrations declined significantly after intramuscular administration of cobalamin. No significant difference was found between mean serum cobalamin concentrations in these seven and in the remaining subjects. We have also established the normal response of S-MMA to standardized oral loading of L-isoleucine: 100 mmol caused a significant average S-MMA increase of 0.072 zmol/L before cobalamin administration vs 0.013 .mol/L after cobalamin, without significant relation to initial S-MMA values. Our results provide a necessary background for interpretation of S-MMA measurements in clinical studies.
Additional Keyphreses: intra-individual variation reference interval nutritional status
Currently, measurement of cobalamin in serum is essentially the only diagnostic tool in clinical chemistry generally available for use in determining whether a patient is cobalamin deficient. However, the clinical value of cobalamin estimations is uncertain. Serum concentrations of cobalamin do not necessarily reflect the cobalamin status of the body. The use of RIAs with purified intrinsic factor to analyze for cobalamin has reduced, but not eliminated, the incidence of falsely normal concentrations of cobalamin measured in serum of subjects with cobalamin deficiency. Current findings in the literature suggest that subtle cobalamin deficiency is indeed clinically significant, and the limitations in using only the serum cobalamin concentration to detect cobalamin deficiency have been widely recognized (1) (2) (3) (4) (5) (6) (7) . The need for an ancillary diagnostic test in patients with low or low-normal serum cobalamin has been emphasized, and testing for methylmalonic acid (MMA) has been recommended (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) and thus provide an indication of functional cobalamin deficiency (8, 9, 18) . Recently, Rasmussen et al. (14) reported that, in contrast to S-MMA, the urinary excretion of MMA in normal subjects is significantly influenced by previous intake of food and that distinction between patients with evidence of cobalamin deficiency and normal subjects may best be achieved by measurements of MMA in serum.
For three reasons, previous studies of MMA in humans (14, 19) led us to believe that the published reference intervals for S-MMA were too high. First, the range (0.05-0.28 mol!L)
noted (14) in serum from 28 healthy volunteers, ages 22-86 years, who all had a normal concentration of cobalamin in serum, were lower than the normal reference ranges reported, e.g., from 0.16 to 0.64 mo1JL in the U.S.A. (20) and from 0.08 to 0.56 molJL in Denmark (21) , both calculated on the basis of determinations on 50 blood donors; however, the donors had not been assessed for cobalamin status.
Second, the finding in normal subjects that S-MMA was not appreciably increased by stressing the biochemical pathway with added protein, fat, and sugar (19) makes it unlikely that the high values encountered in some of the blood donors were due to previous intake of food. Third, Stabler et al. In the present work, we have attempted to define the upper limit for MMA in serum of non-cobalamin-deficient subjects. We examined intra-and interindividual variation and long-term biological variation. We also measured the response of S-MMA to standardized oral loading with L-isoleucine in subjects with normal and high-normal values of S-MMA, so as to establish a normal reference interval for the response to this loading. Finally, we investigated the effect of intramuscular cobalamin both on S-MMA and on the response of S-MMA to isoleucine load.
Specimens and Methods

Subjects
Selection. All 54 members of the laboratory staff, ages 40 years or older, and 31 chief physicians at our hospitals, selected without conscious bias, were asked to participate in the investigation; 64 volunteered. Exclusion criteria were abnormal concentrations of cobalamin or creatimne in serum, or an abnormal erythrocyte mean-cell volume. Four candidate subjects were thus rejected. In the remaining 60 subjects, erythrocyte counts, leukocyte counts, differential leukocyte counts, and platelet counts were all within normal limits, as were results of liver-function tests. Blood hemoglobin was subnormal in one woman with sideropema but normal in the remainder.
All were apparently healthy and in good nutritional state. None took drugs known to interfere with cobalamin metabolism.
Reference individuals.
Blood was obtained (sample 0) from the 60 volunteers on a normal working-day before lunchtime, approximately 5 h after an everyday breakfast. No restrictions were put on intake of snacks, coffee, tea, or other liquid. In two of the 60 subjects, however, we missed the samples.
Consequently the final 11 subjects were selected among the remaining 36 subjects on the basis of having the highest S-MMA values. In advance, we recruited four (two women, ages 40 and 53 years, and two men, ages 43 and 53 years) of the 22 subjects to participate in the long-term study of intra-individual variation.
Experimental Procedure
The experiment started from three days to two weeks after the initial blood collection for determination of 5-MMA (sample 0). Day 1. Blood was collected (sample 1) under circumstances similar to those under which sample 0 was obtained.
Day 2. The protocol began with an overnight (12 h) fast. The first blood sample (sample 2) was drawn at the beginning of a working-day immediately before the subjects were given an oral load of 100 mmol of L-isoleucine (19) . After 5 h (± 0.5) the next blood sample was collected (sample 3) and the subject was given 1 mg (1 mL) of intramuscular cyanocobalamin.
Day 5. The subjects were administered 1mg of intramuscular cyanocobalainin.
Day 8. Sample 4 was obtained under circumstances similar to those on days 0 and 1.
Day 9. The procedure from day 2 was repeated (samples 5 and 6), except that no more cyanocobalamin was administered to the subjects.
Specimens
Blood samples for determination of MMA were taken from an antecubital vein. After coagulation at room temperature for 1 h, serum was separated by centrifligation and stored at -20 #{176}C.
Determinations
MMA in serum was measured by stable-isotope dilution with solid-phase extraction of the sample (21) . MIVIA from 1650 L of serum was quantitatively extracted, together with added methyl-d3-malonic acid (internal standard), onto a small, disposable, strong-anion-exchange column (Bond Elut,#{174} SAX; Analytichem
International, Harbor
City, CA). The sorbent counter-ion was formate. Neutral and basic compounds were washed out with water, and the retained organic acids were eluted with 18 mol/L formic acid reagent. The formic acid was removed by evaporating the resulting extract under a stream of nitrogen at room temperature.
After a methanol rinse, the residue was dissolved in hydrogen chloride, 1.5 mo]JL in cyclohexanol, and incubated at 115 #{176}C for 15 mm. The cyclohexanol was evaporated almost to dryness at 70#{176}C under a gentle stream of nitrogen, and the residue was dissolved in methanol. The dicyclohexyl derivatives were measured by gas chromatography-mass spectrometry with the mass spectrometer in the selected-ion monitoring mode (21 
Results
Analytical Variation
Total analytical variation was assessed during the entire nine-month period. The SD for MMA in a pooled serum kept at -18 #{176}C, assayed on 67 different occasions, was 0.032 at 0.35 mol/L (CV 9.0%). The within-day component of imprecision, as measured on the basis of duplicate determinations and calculated by analysis of variance, was 0.019 jtmoliL (for the mean of two determinations) for 264 samples.
Biological Variation before Intramuscular Cobalamin
Intra-individual variation. The day-to-day variation (SD) as calculated by analysis of variance for samples 0 and 1 from 33 subjects was 0.03 1 tmol/L.
For five to seven weeks, three subjects had blood sampled every week (19 samples); their weekly intra-individual variation (SD) was 0.038 mol/L.
Four subjects had three-monthly (quarterly) samples taken two to four times (12 samples); the three-monthly intra-individual variation (SD) was 0.038 mol/L. No significant difference was found between day-to-day, weekly, and three-monthly intra-individual variations (Ftest, P >0.05). The variation (SD) between an ordinary sample and a sample taken after an overnight fast (sample 2) was 0.031 mol/L, i.e., equal to the intra-individual, day-to-day variation.
Thus fasting vs nonfasting did not introduce any significant component of variation (F-test) .
Interindividual variation. Figure 1 shows the S-MMA (sample 0) measured in 58 subjects. A goodness-of-fit tes did not prove any deviation from the normal distribution (0.90> P >0.80), and no age-or sex-related differences could be demonstrated.
The mean value for S-MMA was 0.21 mol/L (SD 0.094 mol1L, 0.95 confidence interv 0.05-0.37 /.Lmol/L).
Response to oral L-isoleucine. Primarily, we undertoo this part of the study to define the normal response o S-MMA to a standardized oral isoleucine load. In the 3 subjects who underwent the loading test, the 100 mmol o L-isoleucine caused a significant (P <0.001, t-test for pairs increase in S-MMA (see Table 1 ). No significant relatio with sex, age, or initial S-MMA concentration was found.
Effect of Intramuscular Cobalamin
Concentration of MMA in serum. Table 1 shows tha administration of intramuscular cobalamin caused a sig mficant decrease (sample 5 vs sample 2) in S-MMA (t-tes Response to oral L-isoleucine after cobalamin. As Table 1 shows, the response to L-isoleucine decreased significantly after cobalamin administration (t-test for paired comparisons, P <0.0001), but no significant relation to sex, age, or initial S-MMA was found. Figure 3 illustrates the response to loading with L-isoleucine before and after cobalamin supplementation (95% confidence range: -0.043 to 0.187 and -0.083 to 0.109 mol/L, respectively) in contrast to the response in a 67-year-old patient with neurological symptoms caused by cobalamin deficiency in whom the concentration of cobalamin in serum was normal as measured both by the 5-binder assay (358 pmol/L) and by an R-binder assay (743 pmol/L; normal range: 303-933 pmolJL).
U-
DIscussIon
A prerequisite
for the interpretation of S-MMA measurements is knowledge of analytical variation, intra-and interindividual variation, long-term biological variation, and the influence of food intake.
Analytical variation. The results of our evaluation of the assay performance compare reasonably well with those originally reported from our laboratory (21) .
Intra-individual variation. This first investigation of intra-individual variation of S-MMA showed consistency of individual S-MMA. In agreement with a previous study (19) involving a limited number of subjects, our results further showed no evidence of significant influence of previous intake of food on S-MMA. One practical consequence is that S-MMA can be validly determined in serum specimens from fasting as well as nonfasting patients. Recently, Rasmussen et al. (14) reported that in healthy subjects a linear relationship exists between S-MMA and urinary MMA excretion rates; their data were consistent with glomerular ifitration and passive reabsorption by the tubules. Furthermore, the excretion rate in any one individual is relatively constant (19) . Therefore, the consistency of individuals' S-MMA most probably reflects a stable rate of MMA production in the same individuals over a long time. Apart from 5'-deoxyadenosylcobalamin, the determinants of the concentration of MMA in serum are at present unclear. MMA is primarily an intermediary in the catabolism of the two branched-chain amino acids, isoleucine and valine. In healthy subjects, only a fraction (about 3 X 10) of the methylmalonyl-CoA molecules formed in the mitochondria escape conversion to succinyl-CoA (19) . Concentrations of isoleucine and valine in serum are largely controlled by muscle metabolism (22) , and the same may apply to the production of methylmalonyl-CoA.
To what degree the interindividual variations of S-MMA in healthy subjects are correlated to variations of lean body mass was not assessed in the present study.
Response to oral L-isoleucine. The average increases in S-MMA (Table 1) confIrm the results from a preliminary experiment (19) in which loading two college students with either 100 mmol of L-isoleucine or 100 mmol of L-valine led to increases of MMA in serum of about 0.10 moI/L. Earlier investigators (15, 16, 23) , applying various colorimetric and chromatographic methods of analysis, were mostly unable to demonstrate accumulation of MMA in normal human subjects loaded with substances that yield MMA, e.g., valine and isoleucine.
Effect of intramuscular cobalamin.
As mentioned, we suspected that "high-normal" values of S-MMA reported for blood donors in the U.S.A. and in Denmark might come from cobalamin-deficient subjects. Recently Lindenbaum et al. (9) concluded that measurements of S-MMA (and total homocysteine in serum) both before and after treatment with cobalamin provide useful confirmatory evidence of a deficiency of cobalamin. Therefore, our finding is interesting that values of S-MMA just above 0.30 jimollL, encountered in seven subjects (Figure 2 ), declined significantly after administration of cobalamin. What this suppression of high-normal values of S-MMA might account for is at present unclear. The amount of 5'-deoxyadenosylcobalamin in the tissues in normal humans may be insufficient to saturate the methylmalonyl-CoA mutase, as indicated for liver tissue in rat (24) and rabbit (25) in studies on intracellular binding of radioactive cobalamin to cobalamin-dependent apoenzymes.
Another possibility is that the phenomenon may have been caused by mild cobalamin deficiency in some tissues (e.g., muscle cells); if so, these responses to cobalamin indicate that increased S-MMA is an early event in the development of cobalamin deficiency. However, the response of the above seven subjects to L-isoleucine loading, an average S-MM.A increase of 0.077 imol/L (range: -0.058 to 0.146 jmolJL), which does not exceed the response observed in the complete set of probands, does not support a hypothesis of early cobalamin deficiency.
In all 33 probands, response to oral L-isoleucine almost disappeared after cobalamin administration ( Figure 3) ; however, this finding does not prove tissue cobalamin deficiency. A lack of 5'-deoxyadenosylcobalamin in mitochondria in some cells to convert a short-lived surplus of L-methylmalonyl-C0A to succinyl-CoA may indicate that the individual has no excess of 5'-deoxyadenosylcobalamin at the sites of biochemical utilization, but it does not necessarily reflect cobalamin deficiency.
Ongoing studies of healthy elderly people (15 thus far) support our present findings for middle-aged subjects. Four of the 15 had S-MMA values above 0.30 .moL/L (mean 0.37, range 0.32-0.40), which declined to an average of 0.23 (range 0.20-0.28) after intramuscular cobalamin.
In the remaining 11, the mean concentrations were 0.24 and 0.23 zmol/L, before and after cobalamin. The average response to oral L-isoleucine in the four and 11 was 0.146 and 0.105 zmolJL, respectively, and 0.046 and 0.000 jnnoIJL, respectively, before and after intramuscular cobalamin. The correlation between serum cobalamin and S-MMA was -0.59 (P <0.025, n = 15). The mean serum cobalamin concentrations in the four (167 pmol/L, SEM 16 pmol/L) was significantly lower than that in the 11 (318 pmoIJL, SEM 27 pmol/L) subjects; although these data are only preliminary, they hint at the possibility of impaired MMA metabolism early in the development of cobalamin deficiency.
As for the future of this area of investigation, subjects with S-MMA >0.30 mol/L should be studied over a long time to clarify whether they do eventually develop clinical cobalamin deficiency.
In conclusion, our main finding is that the observed upper level of the normal reference values may not be the ideal value for differentiating patients with early tissue cobalamin deficiency from normal subjects. The results o this study provide a necessary background for clinical studies that must include subjects with only slightly increased concentrations of MMA and patients with possible cobalamin deficiency to clarify whether measurements of S-MMA before and after injections of cobalamin, or before and after loading with L-isoleucine, provide the best distinction between cobalamin deficiency and normality.
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